News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.680
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
Next >
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints Fred Hassan as Chair of the Board
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
October 26, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
October 15, 2026
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The Market Just Told You Which Layer Of AI Biology It Is Paying For
September 03, 2026
Issued on behalf of MindWalk Holdings Corp.
From
Market Updates
Via
GlobeNewswire
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 05, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
August 04, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026
Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
June 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
May 29, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Recursion Reports First Quarter Financial Results and Provides Business Update
May 06, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Board Transition
April 30, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
April 29, 2026
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
April 07, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
March 31, 2026
From
Citeline
Via
GlobeNewswire
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
February 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
February 18, 2026
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
February 12, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.